Interestingly, an Akt inhibitor, MK-2206 was shown also to synergize with ruxolitinib in cell lines, MPN primary cells and a retroviral reconstitution model of TpoR W515L mutant 40. The gene discussed is MPL; the disease is myeloproliferative neoplasm.